Abstract | OBJECTIVE: To describe the current evidence for the use of oral antiretroviral (ARV) agents in the treatment of chronic hepatitis B (CHB). DATA SOURCES: STUDY SELECTION AND DATA EXTRACTION: DATA SYNTHESIS: Oral ARVs have revolutionized the treatment of CHB. Studies conducted comparing ARVs have favored entecavir and tenofovir with respect to their ability to decrease hepatitis B virus DNA viral load while minimizing the development of resistance. However, low seroconversion rates, recurrent viremia when ARV therapy is discontinued, and increased resistance rates with longer treatment durations limit the benefit of oral ARVs in the treatment of CHB. Combination therapy has been a suggested solution; however, studies have yet to prove additional benefit over currently recommended monotherapy. CONCLUSIONS: Oral ARVs should continue to be used in the treatment of CHB; however, research is needed to define the optimal duration of therapy, evaluate the utility of combination therapy, and explore novel targets within the hepatitis B life cycle.
|
Authors | Lauren M Hynicka, Nancy Yunker, Punam H Patel |
Journal | The Annals of pharmacotherapy
(Ann Pharmacother)
2010 Jul-Aug
Vol. 44
Issue 7-8
Pg. 1271-86
ISSN: 1542-6270 [Electronic] United States |
PMID | 20587747
(Publication Type: Comparative Study, Journal Article, Review)
|
Chemical References |
- Anti-Retroviral Agents
- DNA, Viral
|
Topics |
- Administration, Oral
- Anti-Retroviral Agents
(administration & dosage, therapeutic use)
- Clinical Trials as Topic
- DNA, Viral
(drug effects)
- Drug Resistance, Viral
- Drug Therapy, Combination
- Hepatitis B, Chronic
(drug therapy)
- Humans
- Viral Load
(drug effects)
|